Back

Validation of the DOAC Score among patients on vitamin K antagonists

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in atrial fibrillation: new insights Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rahul Aggarwal

Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Abstract Slides
Presentation thumbnail
Factor XI inhibitors or direct oral anticoagulants in atrial fibrillation: an updated meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides
Presentation thumbnail
Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Abstract Slides
Presentation thumbnail
Renal function and long-term outcomes in edoxaban-treated patients: A subanalysis from ETNA-AF Europe 4 years follow up
Professor R. De Caterina (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Oral anticoagulation in atrial fibrillation: new insights
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources